One study entitled Targeted Therapy with Lapatanib in Patients with Recurrent Pituitary Tumors Resistant to Standard Therapy (Cedars-Sinai Medical Center et al., United States) examined EGFR-targeted therapy and has been completed, although as yet, no results are available [129]. This evidence concerns the gene EGFR and pituitary tumor.